This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
NEJM.org
nejm.org
did:plc:mgwrki6irihfcatu2v347soc
A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 trial results: nej.md/48VdDZp
#endosky #medsky
https://nej.md/48VdDZp
2024-12-07T15:15:34.417Z